Abstract
Background: Patient-derived xenografts (PDXs) have become the leading model system in oncology drug discovery. Depending on their site of implantation, PDX models from solid tumors can be divided into two categories: subcutaneous (s.c.) and orthotopic (ortho). The advantage of s.c. implantation is that tumor size can be easily monitored, allowing fast validation of drug efficacy. However, since the s.c. microenvironment is likely different from the tissue of origin for most tumor types, there is concern that s.c.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
